Best AI Healthcare Companies in 2026: 8 Tools Compared

#1

Tempus

Best for: Precision oncology and clinical data

Visit tempus.com

Tempus built its business on a simple idea: cancer care produces huge amounts of genomic and clinical data, and most of it used to sit unused. The Chicago company sequences tumors, structures the records around them, and sells oncologists reports that connect a patient's mutations to therapies and trials. Its data library, built from millions of de-identified records, is the asset rivals find hardest to copy.

Tempus is now a public company and has expanded into cardiology and pathology, but oncology remains the core. For a health system or pharma company that wants precision medicine data at scale, Tempus is the first call. For a small clinic that wants a simple tool, it is more platform than it needs.

#2

Aidoc

Best for: Radiology triage and imaging AI

Visit aidoc.com

Aidoc sells an operating system for medical imaging. Its algorithms read scans as they are produced and push suspected strokes, brain bleeds, pulmonary emboli, and other urgent findings to the front of the worklist, so a radiologist sees the sickest patient first. The company reports deployment in more than 1,000 facilities, and its clearances cover a wide set of conditions.

The pitch is time. In stroke and trauma care, minutes change outcomes, and Aidoc sells the minutes. Hospitals with high imaging volume get the most from it. Smaller sites with a handful of scans a day will struggle to justify the platform fee, which is quoted per contract.

#3

Abridge

Best for: Ambient clinical documentation

4.2/5 on G2 (16 reviews, checked Oct 2026)

Visit abridge.com

Abridge records the conversation between a clinician and a patient, with consent, and drafts the clinical note from it. The doctor checks and signs the note instead of typing it after hours. That simple promise, giving clinicians their evenings back, made Abridge one of the fastest growing companies in health AI, with rollouts at large systems such as Kaiser Permanente and Mayo Clinic reported in industry coverage.

Abridge works inside the record systems hospitals already run, which is why it spread quickly. Its limit is scope. It documents care rather than guiding it, and health systems still pay per clinician. For cutting documentation burden, it is the company buyers benchmark against.

#4

Viz.ai

Best for: Care coordination for time critical conditions

Visit viz.ai

Viz.ai pairs detection with coordination. When its algorithms spot a likely large vessel stroke or another urgent finding on a scan, the app alerts the neurologist, surgeon, and care team at once, with the images on their phones. The company built its name in stroke care, where the gap between scan and treatment decides how much brain a patient keeps.

Coordination tools only work when the whole team uses them, so Viz.ai sells hospital by hospital and service line by service line. It has been adding conditions in cardiology and other areas. For systems that measure themselves on door to treatment times, Viz.ai is the standard the rest are compared with.

#5

PathAI

Best for: Digital pathology and biomarker work

Visit pathai.com

PathAI applies image analysis to pathology, the specialty that examines tissue under a microscope. Its models quantify cancer biomarkers and patterns in digitised slides, which helps pathologists score cases more consistently and helps drug companies find the patients most likely to respond to a therapy. Much of its business is with pharmaceutical firms and large labs rather than single hospitals.

The headwind is the lab itself. Many pathology departments still work on glass slides, and scanning them is a project before any AI runs. PathAI sells both the workflow platform and the algorithms to address that. For oncology research and trials, it is one of the most established names in digital pathology.

#6

Recursion

Best for: AI drug discovery with pharma

Visit recursion.com

Recursion runs one of the most automated biology operations in the industry. Robots run experiments on cells, imaging systems record how the cells respond to compounds and genetic changes, and models learn the patterns that point to new drug targets. The company works on its own pipeline and with large pharmaceutical partners, and it absorbed Exscientia to strengthen its chemistry side.

Buyers should be clear about what Recursion is. It is a drug discovery company, not software a hospital deploys, and its results arrive on pharmaceutical timescales. For pharma teams scouting AI discovery partners, though, Recursion is usually on the first list of meetings.

#7

Butterfly Network

Best for: Handheld ultrasound with AI guidance

Visit butterflynetwork.com

Butterfly Network put an ultrasound machine on a chip and sold it as a handheld probe that plugs into a phone or tablet. The Butterfly iQ line gives a clinician at the bedside a way to scan the heart, lungs, abdomen, and more without waiting for a cart, and its AI tools guide probe placement and label anatomy for users who do not scan every day.

It is the one company here that sells something close to a product price, though enterprise deals and software subscriptions still shape the real cost, so this guide lists See website. Butterfly fits emergency, rural, and teaching settings where access matters more than the last degree of image quality.

#8

Owkin

Best for: Federated drug discovery research

Visit owkin.com

Owkin built its name on federated learning, a method that trains models across hospitals without patient data leaving each site. That approach won it a network of academic medical centres and pharmaceutical partners who want to study cancer and other diseases on real world data they could not otherwise combine.

Like Recursion, Owkin sells research capability to pharma and hospitals rather than a tool for the ward. Its recent work adds AI agents that propose hypotheses and plan experiments. For organisations that want discovery research with privacy built into the method, Owkin is a leading option.